@article{0472050c982942e5a582b027c514bbdb,
title = "Emerging Targets for Cardiovascular Disease Prevention in Diabetes",
abstract = "Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke. Recent clinical trials point toward new treatment and prevention strategies for cardiovascular complications of T2DM. New antidiabetic agents show unexpected cardioprotective benefits. Moreover, genetic and reverse translational strategies have revealed potential novel targets for CVD prevention in diabetes, including inhibition of apolipoprotein C3 (APOC3). Modeling and pharmacology-based approaches to improve insulin action provide additional potential strategies to combat CVD. The development of new strategies for improved diabetes and lipid control fuels hope for future prevention of CVD associated with diabetes.",
keywords = "angiopoietin-like, apolipoprotein C3, atherosclerosis, diabetes, genetics, insulin",
author = "Stitziel, {Nathan O.} and Kanter, {Jenny E.} and Bornfeldt, {Karin E.}",
note = "Funding Information: Research in the authors{\textquoteright} laboratories is supported by the American Diabetes Association grant 1-16-IBS-153 and the National Institutes of Health (NIH) grants U24DK076169 and U24DK115255 , subaward 32307-34 to J.E.K., and by NIH grants to N.O.S. (R01HL131961 and UM1HG008853) and K.E.B. (DP3DK108209, R01HL127694, R01HL126028, and P01HL092969), and by the Diabetes Research Center at the University of Washington , P30DK017047 . Funding Information: Research in the authors{\textquoteright} laboratories is supported by the American Diabetes Association grant 1-16-IBS-153 and the National Institutes of Health (NIH) grants U24DK076169 and U24DK115255, subaward 32307-34 to J.E.K. and by NIH grants to N.O.S. (R01HL131961 and UM1HG008853) and K.E.B. (DP3DK108209, R01HL127694, R01HL126028, and P01HL092969), and by the Diabetes Research Center at the University of Washington, P30DK017047. N.O.S. has received an investigator-initiated grant from Regeneron. K.E.B. and J.E.K. have received research support from Novo Nordisk A/S. Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",
year = "2020",
month = aug,
doi = "10.1016/j.molmed.2020.03.011",
language = "English",
volume = "26",
pages = "744--757",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
number = "8",
}